Immune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy.

Ariane Steindl¹, Angelika M Starzer¹, Erwin Tomasich¹, Markus Kleinberger¹, Luzia Berchtold¹, Franziska Eckert², Georg Widhalm³, Brigitte Gatterbauer³, Johannes A Hainfellner⁴, Lisa Wozelka-Oltjan⁵, Bekir Erguener⁶, Michael Schuster⁶, Christoph Bock⁶, Gerwin Heller⁷, Matthias Preusser¹, Anna S Berghoff⁸

¹Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria; Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Division of Oncology, Medical University of Vienna, Austria.

²Department of Radiation Oncology, Medical University of Vienna, Austria.

³Department of Neurosurgery, Medical University of Vienna, Austria.

⁴Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Austria.

⁵Department of Pathology, Medical University of Vienna, Vienna, Austria.

⁶CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Institute of Artificial Intelligence, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

⁷Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria.

⁸Division of Oncology, Department of Medicine I, Medical University of Vienna, Austria; Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Division of Oncology, Medical University of Vienna, Austria. Electronic address: anna.berghoff@meduniwien.ac.at.

PubMed DOI

Abstract

PURPOSE: Given the early recurrence of brain metastasis (BM), identifying factors that drive BM progression is of clinical interest. This study investigates genetic, epigenetic, and inflammatory signatures in progressive BM following different therapeutic approaches. METHODS: A total of 153 patients who underwent surgical resection for progressive BM were grouped according to the therapeutic stra…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.